Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $281 million, representing a 39% year-over-year growth, while full-year revenue reached $982 million, a 33% increase year-over-year [9][31] - Non-GAAP gross margin improved to 66% in Q4 2025, up from 63% in the prior year, driven by a significant reduction in Reveal cost per test [32][33] - Adjusted EBITDA loss improved to $64.9 million in Q4 compared to $78.4 million in the prior year quarter [34] Business Line Data and Key Metrics Changes - Oncology revenue increased 30% to $190 million in Q4, with volumes growing 38% to approximately 79,000 tests [9][29] - Screening revenue totaled $35 million from approximately 38,000 Shield tests in Q4, reflecting strong sequential growth [19][30] - Biopharma and data revenue grew 18% year-over-year to $210 million in 2025 [16][17] Market Data and Key Metrics Changes - Guardant360 Liquid volumes increased nearly 30%, supported by expanding clinical utility from Smart apps launched over the past year [30] - Reveal continued to be the fastest-growing oncology product, benefiting from CRC surveillance reimbursement and early uptake for late-stage therapy response monitoring [12][30] - Shield's adherence rate reached 93% across the first 100,000 tests ordered, significantly higher than other screening modalities [22] Company Strategy and Development Direction - The company aims to expand Shield to include multi-cancer detection results, enhancing its market position [24] - Strategic collaborations with Quest Diagnostics and PathGroup are expected to broaden national reach and enhance commercial infrastructure [23] - The acquisition of MetaSyte Diagnostics is anticipated to enhance the oncology product portfolio and accelerate multi-disease detection capabilities [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, expecting revenue growth of 27%-30% and oncology revenue growth of 25%-27% [36][37] - The company is focused on achieving cash flow breakeven by the end of 2027, with expectations of positive free cash flow from the core business in 2026 [35][40] - Management highlighted the importance of reimbursement wins for therapy monitoring as a significant growth driver for the oncology business [46] Other Important Information - The company reported a significant increase in the commercial team, with approximately 300 sales representatives by the end of 2025 [21] - The ADLT reimbursement rate for Shield is set at $1,495, secured through December 2027, supporting healthy ASP and gross profit [25][39] - The company is actively pursuing FDA approvals for new products, including Guardant360 Liquid CDx for lung cancer [40] Q&A Session Summary Question: Can you elaborate on Reveal therapeutic monitoring and its opportunity? - Management expressed excitement about Reveal for therapy monitoring, emphasizing its synergy with Guardant360 for patient treatment decisions [44][46] Question: How should we think about oncology growth throughout the year? - Management is bullish about 2026, expecting at least 20% growth in Guardant360 volumes and strong performance from Reveal [50][51] Question: What is the expected burn for Shield in 2026? - The company anticipates a similar burn for screening as in 2025, around $220 million, while the rest of the business is expected to be cash flow positive [54][55] Question: What is the latest thinking on ADLT pricing for Guardant360? - Management indicated that no ADLT pricing is baked into the 2026 guidance, with expectations for FDA submission in H2 2026 [59][61] Question: Can you discuss the opt-in rate for MCED Shield and its potential for FDA approval? - Management reported good adoption rates for the MCED offering, with enthusiasm from providers and patients, but did not provide specific numbers [76][78]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $281.3 million, representing a 39% year-over-year growth, while full-year revenue reached $982.0 million, a 33% increase year-over-year [7][28]. - Non-GAAP gross margin improved to 66% in Q4 2025, up from 63% in the prior year, and for the full year, it increased from 62% in 2024 to 66% [29][30]. - Adjusted EBITDA loss improved to $64.9 million in Q4 compared to $78.4 million in the prior year, and for the full year, the loss was $220.9 million versus $257.5 million in 2024 [31]. Business Line Data and Key Metrics Changes - Oncology revenue increased by 30% to $189.9 million in Q4, with approximately 79,000 tests conducted, reflecting a 38% volume growth [25][28]. - Screening revenue totaled $35.1 million from approximately 38,000 Shield tests in Q4, with an average selling price (ASP) of approximately $850 [27][30]. - Biopharma and data revenue grew 9% to $54.0 million, aligning with expectations [27]. Market Data and Key Metrics Changes - The company received Medicare coverage for colorectal cancer (CRC) surveillance in early 2025, which has positively impacted the adoption of Reveal [5]. - The Shield test has shown strong adherence rates of 93% among patients, significantly higher than traditional screening methods [18]. Company Strategy and Development Direction - The company aims to expand its multi-cancer detection capabilities through the Shield platform, which includes a new multi-cancer detection results report [21]. - Strategic partnerships with Quest Diagnostics and PathGroup are expected to enhance national reach and operational capabilities in 2026 [19][20]. - The acquisition of MetaCyte Diagnostics is anticipated to enhance the company's R&D capabilities and accelerate its multi-disease detection pipeline [32]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued strong growth in oncology, projecting a 25%-27% growth rate for oncology revenue in 2026, supported by volume growth of approximately 30% [33]. - The company expects to achieve free cash flow positivity for the core business in 2026, excluding screening, and aims for company-wide cash flow breakeven by the end of 2027 [32][36]. - Management highlighted the importance of reimbursement wins for therapy monitoring as a significant growth driver for the oncology business [42]. Other Important Information - The company has established a robust pipeline of ongoing companion diagnostics (CDx) programs, with 25 approvals to date across various regions [14]. - The company is focused on improving gross margins through ASP optimization and operational efficiencies, with expectations of non-GAAP gross margins in the range of 64%-65% for 2026 [36]. Q&A Session Summary Question: Can you elaborate on Reveal therapeutic monitoring and its opportunity? - Management expressed excitement about Reveal for therapy monitoring, emphasizing its synergy with Guardant360 for patient monitoring and therapeutic decisions [40][42]. Question: How should we think about oncology growth throughout the year? - Management is bullish about 2026, expecting at least 20% growth in Guardant360 volumes and strong performance from Reveal, which is anticipated to remain the fastest-growing product [46][48]. Question: What is the expected burn for Shield in 2026? - The company anticipates a similar burn level for screening as in 2025, around $220 million, while the rest of the business is expected to be free cash flow positive [50][52]. Question: What is the latest on ADLT pricing for Guardant360? - Management indicated that no ADLT pricing is baked into the 2026 guidance, with expectations for FDA submission progress in the second half of the year [58][59]. Question: Can you discuss the opt-in rate for MCED Shield and potential FDA submissions? - Management noted good adoption rates for the MCED offering, with enthusiasm from providers and patients, but did not provide specific numbers [76][78].

Conquering Cancer with Data Q4 2025 & Full Year 2025 Earnings Call February 19, 2026 Safe harbor and non-GAAP disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance ...

Core Insights - BillionToOne has launched two new add-on applications, Northstar PGx and Northstar Select CH, to enhance the Northstar Select platform for liquid biopsy testing, which is designed for advanced solid tumors [1] Group 1: Product Launch and Features - Northstar PGx provides pharmacogenomic insights into key variants in DPYD and UGT1A1, which are critical for fluoropyrimidine and irinotecan-based therapies, helping inform treatment planning without extending turnaround time [1] - Northstar Select CH addresses clonal hematopoiesis, which can lead to false positives in cfDNA testing, achieving over 99% accuracy in distinguishing tumor-derived alterations from non-tumor findings [1] - The integration of these applications into the Northstar workflow allows for comprehensive insights from a single blood draw, enhancing clinical decision-making without adding complexity [1] Group 2: Clinical Validation and Performance - Northstar Select demonstrated superior performance in detecting clinically actionable alterations, identifying 51% more pathogenic single nucleotide variants and 109% more copy number variants compared to other liquid biopsy tests [1] - The assay showed 98% concordance with results from digital droplet PCR, validating its sensitivity and accuracy in clinical settings [1] Group 3: Industry Context and Implications - The launch reflects a commitment to improving oncologists' ability to select appropriate therapies, thereby avoiding ineffective treatments and potential chemotherapy toxicity [1] - Recent guidelines emphasize the importance of broader testing, which aligns with the capabilities of Northstar PGx and Northstar Select CH, supporting the trend towards personalized medicine in oncology [1]

JP Morgan Healthcare Conference J anuary 12, 2026 Safe harbor and non-GAAP disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or i ...

Core Viewpoint - Inspira Technologies is positioning itself to enter the multi-billion dollar liquid biopsy diagnostics market through a proposed acquisition and a strategic equity investment of $15 million, while ensuring protections for existing shareholders [1][2]. Equity Investment - The proposed transaction includes a $15 million equity investment at a premium to the current market capitalization, based on a pre-money valuation of $180 million, reflecting the strategic investor's assessment of the liquid biopsy technology's potential [3]. - The identity of the strategic investor will be disclosed after shareholder approval and execution of definitive agreements, with $12 million of the investment proceeds allocated to fund existing technologies [4]. Strategic Acquisition - The acquisition involves an advanced liquid biopsy diagnostics business, allowing Inspira to enter the growing liquid biopsy market with a proprietary platform designed for cancer characterization [5]. - The platform has shown high concordance with traditional tissue biopsy in clinical studies, indicating its potential to provide valuable diagnostic insights [5][6]. - The initial clinical focus of the platform is on breast cancer, with a projected global liquid biopsy market size of approximately $58 billion over the next decade [6]. Regulatory Pathway - Following the acquisition, the company plans to pursue FDA clearance for the liquid biopsy platform through the 510(k) regulatory pathway, leveraging existing regulatory precedents [7]. - An existing reimbursement code is already in place for the intended clinical use, facilitating a clear path to reimbursement upon regulatory clearance [8]. Shareholder Protection Framework - The transaction includes a shareholder protection framework to preserve the economic upside of existing technologies for current shareholders while allowing participation in the growth potential of the liquid biopsy platform [9]. - Existing shareholders are expected to receive contingent value rights, ensuring that future realizations of value from respiratory technology assets are allocated exclusively to them [9]. Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products and a growing IP portfolio [10].

Core Insights - VolitionRx Limited has announced a new manuscript detailing a novel method, Capture-Seq™, for detecting cancer biomarkers through the analysis of transcription factor protected cfDNA in plasma, which promises accurate and low-cost cancer tests [1][3][4] Technology and Methodology - The new method allows for the physical enrichment of ultrashort DNA fragments bound to transcription factors, achieving a 180-fold enrichment (18,000%) compared to traditional methods that lose the DNA's chromosomal context [2][4] - By isolating ultrashort transcription factor-bound DNA, Volition's technology effectively removes 99% of background DNA, addressing the challenge of interference in liquid biopsy tests for early-stage cancer [4][5] Clinical Results - In a small training cohort of 70 individuals, including 49 cancer patients, the analysis demonstrated 100% sensitivity and specificity in detecting cancer, including early-stage cases [7] Commercial Potential - The company sees significant commercial opportunities with a Total Addressable Market estimated at approximately $23 billion annually, and is actively seeking partnerships to accelerate the technology's integration and launch [9][10] Company Overview - VolitionRx is focused on advancing epigenetics and developing cost-effective blood tests for early disease detection and monitoring, with research and development activities centered in Belgium and additional offices in the U.S. and London [10][11]

Company Overview - Telo Genomics Corp. is a Toronto-based biotech company specializing in diagnostic and prognostic innovations through its proprietary multi-factor telomere analytics platform [1] - The company focuses on liquid biopsies and related technologies in oncology and neurological diseases, which are less invasive and more easily replicated than traditional diagnostic methods [5] - Telo Genomics has developed products that improve patient care by addressing the needs of pathologists, clinicians, academic researchers, and drug developers [5] Recent Developments - Guido Baechler, Executive Chairman, will present at the Small Cap Growth Virtual Investor Conference on December 9th, 2025 [1] - The company has initiated a multiple myeloma MRD clinical trial in collaboration with Cleveland Clinic Cancer Institute, utilizing Telo's 3D telomere analysis [8] - Telo Genomics has relocated to a larger, state-of-the-art clinical lab in the Greater Toronto Area [8] Clinical Applications - The lead application, Telo-MM, aims to provide actionable information for medical professionals treating Multiple Myeloma, a severe form of blood cancer [5] - Telo Genomics' technology has been validated in over 160 peer-reviewed publications and 30+ clinical studies involving more than 3,000 patients with various cancers and Alzheimer's disease [5] - The company presented interim data from its MM-MRD study at the American Society of Hematology Annual Meeting [8] Investor Engagement - The Virtual Investor Conferences (VIC) provide an interactive platform for publicly traded companies to present directly to investors [6] - The upcoming conference will allow real-time questions from investors, with an archived webcast available for those unable to attend live [2][3]

Core Insights - BioNexus Gene Lab Corp. (BGLC) has entered into an Exclusive Intellectual Property License Agreement with Fidelion Diagnostics for the VitaGuard™ minimal residual disease (MRD) liquid biopsy platform in Southeast Asia [1][2][3] License Agreement Details - The license grants BGLC exclusive, irrevocable, royalty-free rights to use, develop, manufacture, market, distribute, and sell VitaGuard-based products and services in Southeast Asia [3] - BGLC will pay Fidelion a US$2 million license fee in 24 equal monthly installments and commit to at least US$500,000 in VitaGuard reagent and system purchases within the first 24 months [4] - The agreement is structured as a perpetual license, ensuring rights remain even if ownership of the underlying patents changes [5] Strategic Framework - The license agreement is part of a broader Share Subscription and Shareholders' Agreement, which positions BGLC as a strategic shareholder in Fidelion [2][6] - Management believes this agreement transforms a strategic framework into an operational business, enhancing BGLC's position in the MRD testing market [7] Market Potential - The global liquid biopsy market is projected to grow from approximately US$13.3 billion in 2025 to over US$22.88 billion by 2030, indicating a significant compound annual growth rate [9] - The MRD market is expected to increase from about US$1.4 billion in 2024 to roughly US$2.5 billion by 2029, representing a CAGR of over 12% [10] Regional Insights - Southeast Asia faces a rising cancer burden, with WHO estimating around 2.3–2.4 million new cancer cases and 1.5 million cancer deaths in 2022, with projections of an 80–85% increase in new cases by 2050 [13] - The region remains underpenetrated in advanced molecular diagnostics, with limited access to MRD testing outside a few top centers [14] - BGLC aims to establish itself as a first mover in the MRD market in Southeast Asia, focusing on building a recurring-revenue platform and a top-tier lab network [15]

Summary of CelLBxHealth plc Investor Presentation Company Overview - **Company**: CelLBxHealth plc (formerly Angle) - **Industry**: Liquid Biopsy and Oncology Diagnostics - **Key Executives**: - Peter Collins, CEO - Sinead Armstrong, FD - Dr. Jan Groen, Executive Chairman (not present) Core Points and Arguments - **Market Opportunity**: The total addressable market for circulating tumor cells (CTCs) is growing at approximately 12% annually, indicating a significant clinical need for advancements in cancer diagnostics beyond circulating tumor DNA (ctDNA) [5][6][12] - **Business Model Shift**: The company is transitioning from academic collaborations to a focused commercialization strategy, aiming to increase the adoption of its Parsortix platform through strategic partnerships and lab service providers [6][14] - **Sales Pipeline**: CelLBxHealth has a well-qualified sales pipeline valued at GBP 12.6 million, with expectations of generating GBP 4.5 million in revenue over the next two years [7][21] - **Funding and Financial Outlook**: The company has successfully raised GBP 6.8 million and plans to achieve cash flow break-even by the end of 2028, with a projected revenue of GBP 8 million in the medium term [8][22][25] - **Clinical Utility of CTCs**: There is a growing recognition of the limitations of ctDNA, with CTCs being positioned as a more reliable source of real-time tumor information, which is critical for patient management and drug development [10][37] - **Strategic Partnerships**: Collaborations with major players like Myriad Genetics and Roche are expected to enhance the company's market position and facilitate the integration of CTC testing into existing workflows [16][17][18] Additional Important Insights - **Operational Restructuring**: The company plans to reduce its workforce from 108 to approximately 44 employees to streamline operations and focus on revenue-generating activities [25][28] - **Regulatory Landscape**: The FDA's oversight of laboratory-developed tests (LDTs) remains a complex issue, but the company is optimistic about navigating this landscape to enhance its offerings [34] - **Future Growth Potential**: The company anticipates significant growth opportunities as it addresses the unmet needs in cancer diagnostics, particularly in the context of high failure rates associated with current testing methods [19][24][37] - **Market Validation**: The Parsortix platform has been recognized as a best-in-class sample preparation technology for CTCs, with substantial clinical validity data supporting its use across various cancer types [12][14] Conclusion CelLBxHealth is poised for growth in the oncology diagnostics market through a strategic focus on circulating tumor cells, operational restructuring, and strong partnerships. The company aims to leverage its technology to improve patient outcomes and drive revenue growth, with a clear path to profitability by 2028.